FOLH1 and prostate cancer: When compared to conventional imaging, prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) has higher detection rates and greater diagnostic accuracy for patients with initial high risk, biochemically recurrent or persistent prostate cancer, and mCRPC (6–9).